Review



umab61  (OriGene)


Bioz Verified Symbol OriGene is a verified supplier
Bioz Manufacturer Symbol OriGene manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    OriGene umab61
    Umab61, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd1c/CD1C+Mouse+Monoclonal+Antibody/us09758583-208-46-47
    Average 93 stars, based on 3 article reviews
    umab61 - by Bioz Stars, 2026-11
    93/100 stars

    Images

    Related Articles

    Binding Assay:

    Article Title: Anti-CTLA-4 antibodies
    Article Snippet: .. In some embodiments, the antigen binding fragment for BTLA may comprise the CDRs, light and heavy chain variable domains or other BTLA binding fragment of e.g. anti-BTLA antibody clone 1B7, clone 2G8, clone 4C5 (Abnova Corporation), clone 4B8 (antibodies-online), clone MIH26 (Thermo Scientific Pierce Antibodies), clone UMAB61 (OriGene Technologies), clone 330104 (R&D Systems), clone 1B4 (LifeSpan BioSciences), clone 440205, clone 5E7 (Creative Diagnostics). .. In some embodiments, the antigen binding fragment for LAG-3 may comprise the CDRs, light and heavy chain variable domains or other LAG-3 binding fragment of e.g. anti-LAG-3 antibody clone 17B4 (Enzo Life Sciences), clone 333210 (R&D Systems), clone 14L676 (United States Biological), BMS-986016, or an anti-LAG-3 antibody described in WO 2015042246 A1.

    Article Title: Anti-PD-L1 antibodies
    Article Snippet: .. In some embodiments, the antigen binding fragment for BTLA may comprise the CDRs, light and heavy chain variable domains or other BTLA binding fragment of e.g. anti-BTLA antibody clone 1B7, clone 2G8, clone 4C5 (Abnova Corporation), clone 4B8 (antibodies-online), clone MIH26 (THERMO SCIENTIFIC® Pierce Antibodies), clone UMAB61 (OriGene Technologies), clone 330104 (R&D Systems), clone 1B4 (LifeSpan BioSciences), clone 440205, clone 5E7 (Creative Diagnostics). .. In some embodiments, the antigen binding fragment for CTLA4 may comprise the CDRs, light and heavy chain variable domains or other CTLA4 binding fragment of e.g. anti-CTLA4 antibody clone 2F1, clone 1 F4 (Abnova Corporation), clone 9H10 (EMD Millipore), clone BNU3 (GeneTex), clone 1 E2, clone AS32 (LifeSpan BioSciences) clone A3.4H2.H12 (Acris Antibodies), clone 060 (Sino Biological), clone BU5G3 (Creative Diagnostics), clone MIH8 (MBL International), clone A3.6B10.G1, or clone L3D10 (BIOLEGEND®).

    Article Title: Anti-PD-1 antibodies
    Article Snippet: In some embodiments, the antigen binding domain for CTLA4 may comprise the CDRs, light and heavy chain variable domains or other CTLA4 binding fragment of e.g. anti-CTLA4 antibody clone 2F1, clone 1F4 (Abnova Corporation), clone 9H10 (EMD Millipore), clone BNU3 (GeneTex), clone 1E2, clone AS32 (LifeSpan BioSciences) clone A3.4H2.H12 (Acris Antibodies), clone 060 (Sino Biological), clone BU5G3 (Creative Diagnostics), clone MIH8 (MBL International), clone A3.6B10.G1, or clone L3D10 (BioLegend). .. In some embodiments, the antigen binding domain for BTLA may comprise the CDRs, light and heavy chain variable domains or other BTLA binding fragment of e.g. anti-BTLA antibody clone 1B7, clone 2G8, clone 4C5 (Abnova Corporation), clone 4B8 (antibodies-online), clone MIH26 (Thermo Scientific Pierce Antibodies), clone UMAB61 (OriGene Technologies), clone 330104 (R&D Systems), clone 1B4 (LifeSpan BioSciences), clone 440205, clone 5E7 (Creative Diagnostics). .. In some embodiments, the antigen binding domain for CD28 may comprise the CDRs, light and heavy chain variable domains or other CD28 binding fragment of e.g. anti-CD28 antibody clone CD28.6 (eBioscience), clone CD28.2, clone JJ319 (Novus Biologicals), clone 204.12, clone B-23, clone 10F3 (Thermo Scientific Pierce Antibodies), clone 37407 (R&D Systems), clone 204-12 (Abnova Corporation), clone 15E8 (EMD Millipore), clone 204-12, clone YTH913.12 (AbD Serotec), clone B-T3 (Acris Antibodies), clone 9H6E2 (Sino Biological), clone C28/77 (MyBioSource.com), clone KOLT-2 (ALPCO), clone 152-2E10 (Santa Cruz Biotechnology), or clone XPH-56 (Creative Diagnostics).



    Similar Products

    95
    Miltenyi Biotec dc2s
    Ex vivo-generated cDC1s and cDC2s acquire a matured state upon TLR challenge. Enriched cDC1s and cDC2s were overnight stimulated with a maturation cocktail containing R848 and Poly(IC), and the next day, their phenotype and cytokine/chemokine production were characterized. (A) Representative histograms showing the expression levels of CD83, CD40, and CCR7 upon maturation on <t>DC2s</t> (blue histograms) and cDC1s (red histograms). (B) Maturation marker expression on cDC2s (blue dots) and cDC1s (red dots) is displayed as either percentage of positive DCs (CD80, CD86, CD83, CD40, and CCR7) or relative geometric mean fluorescence intensity (gMFI) (HLA-DR). Relative gMFI expression was determined by normalizing to the average gMFI of untreated cDC1s or cDC2s. Scatter dot plots show the mean ± SEM with each data point representing an individual DC donor ( n ≥ 8). (C) Scatter dot plots show the mean ± SEM of the raw concentrations of the indicated cytokines and chemokines. Each data point represents an individual DC donor ( n ≥ 8). Statistical significance was calculated for paired data sets with a paired t-test or a Wilcoxon test, whereas for unpaired data sets significancy was calculated using a Mann–Whitney test. * P < 0.05; ** P < 0.01; *** P < 0.001.
    Dc2s, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd1c/CD1c+(BDCA-1)+Antibody%2C+anti-human/pmc13336304-91-12-16
    Average 95 stars, based on 1 article reviews
    dc2s - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    92
    Miltenyi Biotec cd1c
    Ex vivo-generated cDC1s and cDC2s acquire a matured state upon TLR challenge. Enriched cDC1s and cDC2s were overnight stimulated with a maturation cocktail containing R848 and Poly(IC), and the next day, their phenotype and cytokine/chemokine production were characterized. (A) Representative histograms showing the expression levels of CD83, CD40, and CCR7 upon maturation on <t>DC2s</t> (blue histograms) and cDC1s (red histograms). (B) Maturation marker expression on cDC2s (blue dots) and cDC1s (red dots) is displayed as either percentage of positive DCs (CD80, CD86, CD83, CD40, and CCR7) or relative geometric mean fluorescence intensity (gMFI) (HLA-DR). Relative gMFI expression was determined by normalizing to the average gMFI of untreated cDC1s or cDC2s. Scatter dot plots show the mean ± SEM with each data point representing an individual DC donor ( n ≥ 8). (C) Scatter dot plots show the mean ± SEM of the raw concentrations of the indicated cytokines and chemokines. Each data point represents an individual DC donor ( n ≥ 8). Statistical significance was calculated for paired data sets with a paired t-test or a Wilcoxon test, whereas for unpaired data sets significancy was calculated using a Mann–Whitney test. * P < 0.05; ** P < 0.01; *** P < 0.001.
    Cd1c, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd1c/CD1c+(BDCA-1)+Antibody%2C+anti-human%2C+REAfinity/pm42946878-339-62-65
    Average 92 stars, based on 1 article reviews
    cd1c - by Bioz Stars, 2026-11
    92/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec cd14 microbeads miltenyi biotec
    Ex vivo-generated cDC1s and cDC2s acquire a matured state upon TLR challenge. Enriched cDC1s and cDC2s were overnight stimulated with a maturation cocktail containing R848 and Poly(IC), and the next day, their phenotype and cytokine/chemokine production were characterized. (A) Representative histograms showing the expression levels of CD83, CD40, and CCR7 upon maturation on <t>DC2s</t> (blue histograms) and cDC1s (red histograms). (B) Maturation marker expression on cDC2s (blue dots) and cDC1s (red dots) is displayed as either percentage of positive DCs (CD80, CD86, CD83, CD40, and CCR7) or relative geometric mean fluorescence intensity (gMFI) (HLA-DR). Relative gMFI expression was determined by normalizing to the average gMFI of untreated cDC1s or cDC2s. Scatter dot plots show the mean ± SEM with each data point representing an individual DC donor ( n ≥ 8). (C) Scatter dot plots show the mean ± SEM of the raw concentrations of the indicated cytokines and chemokines. Each data point represents an individual DC donor ( n ≥ 8). Statistical significance was calculated for paired data sets with a paired t-test or a Wilcoxon test, whereas for unpaired data sets significancy was calculated using a Mann–Whitney test. * P < 0.05; ** P < 0.01; *** P < 0.001.
    Cd14 Microbeads Miltenyi Biotec, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd1c/CD1c+(BDCA-1)%2B+Dendritic+Cell+Isolation+Kit%2C+human/10__1016_slash_j__isci__2026__116736-639-174-176
    Average 94 stars, based on 1 article reviews
    cd14 microbeads miltenyi biotec - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec cd1c isolation kit
    CD34-derived cDC1s and cDC2s can be generated from blood progenitors. CD34-positive cells isolated from blood were differentiated into cDC1s and cDC2s in a 17-day protocol in which progenitors initially expand and afterward undergo skewing towards cDC1 and cDC2 differentiation. (A) Schematic representation of the 17-day protocol for DC generation. (B) Bar graph showing the percentage of cDC1s and cDC2s ± SEM at the end of the culture on day 17 ( n = 10). (C) Representative dot plot showing the presence of cDC1s and cDC2s based on the expression of CD141/CLEC9A and <t>CD1c,</t> respectively, after gating on viable single cells. (D) Violin plot showing the absolute number of cDC1s and cDC2s obtained with the current protocol, depending on the initial amount of cultured CD34-positive cells. Each dot represents the value of expanded cDC1s and cDC2s obtained from one independent donor ( n = 12). (E) Bar graphs show the percentage of positive DCs ± SEM for the given marker ( n = 3). CD34-derived cDC1s and cDC2s were characterized by flow cytometry to determine their lineage marker expression.
    Cd1c Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd1c/CD1c+(BDCA-1)%2B+Dendritic+Cell+Isolation+Kit%2C+human/pmc13336304-47-12-16
    Average 94 stars, based on 1 article reviews
    cd1c isolation kit - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    86
    Huabio Inc cd1c
    TLS RiskScore association with response to PD-1 blockade and protein-level implementation in FFPE HCC. (A, B) External anti–PD-1-treated HCC cohort: TLS RiskScore by response status (A) and response rates by TLS RiskScore group using the median cutoff (B) . In (B) , colors indicate the within-group proportions of responders and non-responders within each TLS RiskScore group. (C) Spatial transcriptomics mapping canonical TLS-associated chemokines (CXCL13, CCL19, CCL21) and signature signals for regulatory T cells (Treg) and conventional type 2 dendritic cells (cDC2) in representative HCC sections. (D, E) Representative TLS regions in FFPE HCC illustrating cDC2-predominant versus Treg-predominant cellular composition by H&E and multiplex immunofluorescence (mIF) staining (CD11c, <t>CD1c,</t> CD4, FOXP3, CD45, CD21). (F, G) Overall survival (OS) (F) and progression-free survival (PFS) (G) stratified by an mIF-based TLS RiskScore derived from TLS-region Treg (CD4 + FOXP3 + ) and cDC2 (CD11c + CD1c + ) measurements (median cutoff). (H) cDC2 fractions across TLS maturation stages. (I) Treg-to-cDC2 ratio across TLS maturation stages. **P < 0.01 and ****P < 0.0001.
    Cd1c, supplied by Huabio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd1c/anti+cyclin+d1/pmc13253696-70-20-21
    Average 86 stars, based on 1 article reviews
    cd1c - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    92
    OriGene cd1c
    TLS RiskScore association with response to PD-1 blockade and protein-level implementation in FFPE HCC. (A, B) External anti–PD-1-treated HCC cohort: TLS RiskScore by response status (A) and response rates by TLS RiskScore group using the median cutoff (B) . In (B) , colors indicate the within-group proportions of responders and non-responders within each TLS RiskScore group. (C) Spatial transcriptomics mapping canonical TLS-associated chemokines (CXCL13, CCL19, CCL21) and signature signals for regulatory T cells (Treg) and conventional type 2 dendritic cells (cDC2) in representative HCC sections. (D, E) Representative TLS regions in FFPE HCC illustrating cDC2-predominant versus Treg-predominant cellular composition by H&E and multiplex immunofluorescence (mIF) staining (CD11c, <t>CD1c,</t> CD4, FOXP3, CD45, CD21). (F, G) Overall survival (OS) (F) and progression-free survival (PFS) (G) stratified by an mIF-based TLS RiskScore derived from TLS-region Treg (CD4 + FOXP3 + ) and cDC2 (CD11c + CD1c + ) measurements (median cutoff). (H) cDC2 fractions across TLS maturation stages. (I) Treg-to-cDC2 ratio across TLS maturation stages. **P < 0.01 and ****P < 0.0001.
    Cd1c, supplied by OriGene, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd1c/CD1C+Mouse+Monoclonal+Antibody/pmc13388912__41467_2026_73788_MOESM4_ESM-85-32-33
    Average 92 stars, based on 1 article reviews
    cd1c - by Bioz Stars, 2026-11
    92/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec human miltenyi biotec
    TLS RiskScore association with response to PD-1 blockade and protein-level implementation in FFPE HCC. (A, B) External anti–PD-1-treated HCC cohort: TLS RiskScore by response status (A) and response rates by TLS RiskScore group using the median cutoff (B) . In (B) , colors indicate the within-group proportions of responders and non-responders within each TLS RiskScore group. (C) Spatial transcriptomics mapping canonical TLS-associated chemokines (CXCL13, CCL19, CCL21) and signature signals for regulatory T cells (Treg) and conventional type 2 dendritic cells (cDC2) in representative HCC sections. (D, E) Representative TLS regions in FFPE HCC illustrating cDC2-predominant versus Treg-predominant cellular composition by H&E and multiplex immunofluorescence (mIF) staining (CD11c, <t>CD1c,</t> CD4, FOXP3, CD45, CD21). (F, G) Overall survival (OS) (F) and progression-free survival (PFS) (G) stratified by an mIF-based TLS RiskScore derived from TLS-region Treg (CD4 + FOXP3 + ) and cDC2 (CD11c + CD1c + ) measurements (median cutoff). (H) cDC2 fractions across TLS maturation stages. (I) Treg-to-cDC2 ratio across TLS maturation stages. **P < 0.01 and ****P < 0.0001.
    Human Miltenyi Biotec, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd1c/CD1c+(BDCA-1)%2B+Dendritic+Cell+Isolation+Kit%2C+human/pm41997138-350-266-267
    Average 94 stars, based on 1 article reviews
    human miltenyi biotec - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Cytek Biosciences cflour r668 anti human cd1c
    TLS RiskScore association with response to PD-1 blockade and protein-level implementation in FFPE HCC. (A, B) External anti–PD-1-treated HCC cohort: TLS RiskScore by response status (A) and response rates by TLS RiskScore group using the median cutoff (B) . In (B) , colors indicate the within-group proportions of responders and non-responders within each TLS RiskScore group. (C) Spatial transcriptomics mapping canonical TLS-associated chemokines (CXCL13, CCL19, CCL21) and signature signals for regulatory T cells (Treg) and conventional type 2 dendritic cells (cDC2) in representative HCC sections. (D, E) Representative TLS regions in FFPE HCC illustrating cDC2-predominant versus Treg-predominant cellular composition by H&E and multiplex immunofluorescence (mIF) staining (CD11c, <t>CD1c,</t> CD4, FOXP3, CD45, CD21). (F, G) Overall survival (OS) (F) and progression-free survival (PFS) (G) stratified by an mIF-based TLS RiskScore derived from TLS-region Treg (CD4 + FOXP3 + ) and cDC2 (CD11c + CD1c + ) measurements (median cutoff). (H) cDC2 fractions across TLS maturation stages. (I) Treg-to-cDC2 ratio across TLS maturation stages. **P < 0.01 and ****P < 0.0001.
    Cflour R668 Anti Human Cd1c, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd1c/cFluor+R668+Anti-Human+CD1c/pmc12964223-35-0-7
    Average 94 stars, based on 1 article reviews
    cflour r668 anti human cd1c - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    95
    Miltenyi Biotec anti human cd1c bdca1
    TLS RiskScore association with response to PD-1 blockade and protein-level implementation in FFPE HCC. (A, B) External anti–PD-1-treated HCC cohort: TLS RiskScore by response status (A) and response rates by TLS RiskScore group using the median cutoff (B) . In (B) , colors indicate the within-group proportions of responders and non-responders within each TLS RiskScore group. (C) Spatial transcriptomics mapping canonical TLS-associated chemokines (CXCL13, CCL19, CCL21) and signature signals for regulatory T cells (Treg) and conventional type 2 dendritic cells (cDC2) in representative HCC sections. (D, E) Representative TLS regions in FFPE HCC illustrating cDC2-predominant versus Treg-predominant cellular composition by H&E and multiplex immunofluorescence (mIF) staining (CD11c, <t>CD1c,</t> CD4, FOXP3, CD45, CD21). (F, G) Overall survival (OS) (F) and progression-free survival (PFS) (G) stratified by an mIF-based TLS RiskScore derived from TLS-region Treg (CD4 + FOXP3 + ) and cDC2 (CD11c + CD1c + ) measurements (median cutoff). (H) cDC2 fractions across TLS maturation stages. (I) Treg-to-cDC2 ratio across TLS maturation stages. **P < 0.01 and ****P < 0.0001.
    Anti Human Cd1c Bdca1, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd1c/CD1c+(BDCA-1)+Antibody%2C+anti-human/pm41707448-99-118-125
    Average 95 stars, based on 1 article reviews
    anti human cd1c bdca1 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec miltenyi biotech cd1c
    TLS RiskScore association with response to PD-1 blockade and protein-level implementation in FFPE HCC. (A, B) External anti–PD-1-treated HCC cohort: TLS RiskScore by response status (A) and response rates by TLS RiskScore group using the median cutoff (B) . In (B) , colors indicate the within-group proportions of responders and non-responders within each TLS RiskScore group. (C) Spatial transcriptomics mapping canonical TLS-associated chemokines (CXCL13, CCL19, CCL21) and signature signals for regulatory T cells (Treg) and conventional type 2 dendritic cells (cDC2) in representative HCC sections. (D, E) Representative TLS regions in FFPE HCC illustrating cDC2-predominant versus Treg-predominant cellular composition by H&E and multiplex immunofluorescence (mIF) staining (CD11c, <t>CD1c,</t> CD4, FOXP3, CD45, CD21). (F, G) Overall survival (OS) (F) and progression-free survival (PFS) (G) stratified by an mIF-based TLS RiskScore derived from TLS-region Treg (CD4 + FOXP3 + ) and cDC2 (CD11c + CD1c + ) measurements (median cutoff). (H) cDC2 fractions across TLS maturation stages. (I) Treg-to-cDC2 ratio across TLS maturation stages. **P < 0.01 and ****P < 0.0001.
    Miltenyi Biotech Cd1c, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd1c/CD1c+(BDCA-1)%2B+Dendritic+Cell+Isolation+Kit%2C+non-human+primate/pm41604686-80-19-19
    Average 94 stars, based on 1 article reviews
    miltenyi biotech cd1c - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    Image Search Results


    Ex vivo-generated cDC1s and cDC2s acquire a matured state upon TLR challenge. Enriched cDC1s and cDC2s were overnight stimulated with a maturation cocktail containing R848 and Poly(IC), and the next day, their phenotype and cytokine/chemokine production were characterized. (A) Representative histograms showing the expression levels of CD83, CD40, and CCR7 upon maturation on DC2s (blue histograms) and cDC1s (red histograms). (B) Maturation marker expression on cDC2s (blue dots) and cDC1s (red dots) is displayed as either percentage of positive DCs (CD80, CD86, CD83, CD40, and CCR7) or relative geometric mean fluorescence intensity (gMFI) (HLA-DR). Relative gMFI expression was determined by normalizing to the average gMFI of untreated cDC1s or cDC2s. Scatter dot plots show the mean ± SEM with each data point representing an individual DC donor ( n ≥ 8). (C) Scatter dot plots show the mean ± SEM of the raw concentrations of the indicated cytokines and chemokines. Each data point represents an individual DC donor ( n ≥ 8). Statistical significance was calculated for paired data sets with a paired t-test or a Wilcoxon test, whereas for unpaired data sets significancy was calculated using a Mann–Whitney test. * P < 0.05; ** P < 0.01; *** P < 0.001.

    Journal: Oncoimmunology

    Article Title: Ex vivo-generated conventional dendritic cells type 1 and type 2 from blood progenitors induce potent antigen-specific T-cell immunity

    doi: 10.1080/2162402X.2026.2695692

    Figure Lengend Snippet: Ex vivo-generated cDC1s and cDC2s acquire a matured state upon TLR challenge. Enriched cDC1s and cDC2s were overnight stimulated with a maturation cocktail containing R848 and Poly(IC), and the next day, their phenotype and cytokine/chemokine production were characterized. (A) Representative histograms showing the expression levels of CD83, CD40, and CCR7 upon maturation on DC2s (blue histograms) and cDC1s (red histograms). (B) Maturation marker expression on cDC2s (blue dots) and cDC1s (red dots) is displayed as either percentage of positive DCs (CD80, CD86, CD83, CD40, and CCR7) or relative geometric mean fluorescence intensity (gMFI) (HLA-DR). Relative gMFI expression was determined by normalizing to the average gMFI of untreated cDC1s or cDC2s. Scatter dot plots show the mean ± SEM with each data point representing an individual DC donor ( n ≥ 8). (C) Scatter dot plots show the mean ± SEM of the raw concentrations of the indicated cytokines and chemokines. Each data point represents an individual DC donor ( n ≥ 8). Statistical significance was calculated for paired data sets with a paired t-test or a Wilcoxon test, whereas for unpaired data sets significancy was calculated using a Mann–Whitney test. * P < 0.05; ** P < 0.01; *** P < 0.001.

    Article Snippet: After 2 h of coculture at 37oC, cells were stained to identify DC2s (CD1c-FITC, 1:25, 130-113-301, Miltenyi Biotec) and cDC1s (CD141 PerCP-Cy5.5, 1:25, 344112, BioLegend) prior to analysis using a BD FACSLyricTM.

    Techniques: Ex Vivo, Generated, Expressing, Marker, Fluorescence, MANN-WHITNEY

    CD34-derived cDC1s and cDC2s can be generated from blood progenitors. CD34-positive cells isolated from blood were differentiated into cDC1s and cDC2s in a 17-day protocol in which progenitors initially expand and afterward undergo skewing towards cDC1 and cDC2 differentiation. (A) Schematic representation of the 17-day protocol for DC generation. (B) Bar graph showing the percentage of cDC1s and cDC2s ± SEM at the end of the culture on day 17 ( n = 10). (C) Representative dot plot showing the presence of cDC1s and cDC2s based on the expression of CD141/CLEC9A and CD1c, respectively, after gating on viable single cells. (D) Violin plot showing the absolute number of cDC1s and cDC2s obtained with the current protocol, depending on the initial amount of cultured CD34-positive cells. Each dot represents the value of expanded cDC1s and cDC2s obtained from one independent donor ( n = 12). (E) Bar graphs show the percentage of positive DCs ± SEM for the given marker ( n = 3). CD34-derived cDC1s and cDC2s were characterized by flow cytometry to determine their lineage marker expression.

    Journal: Oncoimmunology

    Article Title: Ex vivo-generated conventional dendritic cells type 1 and type 2 from blood progenitors induce potent antigen-specific T-cell immunity

    doi: 10.1080/2162402X.2026.2695692

    Figure Lengend Snippet: CD34-derived cDC1s and cDC2s can be generated from blood progenitors. CD34-positive cells isolated from blood were differentiated into cDC1s and cDC2s in a 17-day protocol in which progenitors initially expand and afterward undergo skewing towards cDC1 and cDC2 differentiation. (A) Schematic representation of the 17-day protocol for DC generation. (B) Bar graph showing the percentage of cDC1s and cDC2s ± SEM at the end of the culture on day 17 ( n = 10). (C) Representative dot plot showing the presence of cDC1s and cDC2s based on the expression of CD141/CLEC9A and CD1c, respectively, after gating on viable single cells. (D) Violin plot showing the absolute number of cDC1s and cDC2s obtained with the current protocol, depending on the initial amount of cultured CD34-positive cells. Each dot represents the value of expanded cDC1s and cDC2s obtained from one independent donor ( n = 12). (E) Bar graphs show the percentage of positive DCs ± SEM for the given marker ( n = 3). CD34-derived cDC1s and cDC2s were characterized by flow cytometry to determine their lineage marker expression.

    Article Snippet: Alternatively, DCs were enriched by MACS using CD141-Microbeads (130-090-512, Miltenyi Biotec) and CD1c Isolation kit (130-119-475, Miltenyi Biotec) sequentially (see supplementary figure 1C).

    Techniques: Derivative Assay, Generated, Isolation, Expressing, Cell Culture, Marker, Flow Cytometry

    TLS RiskScore association with response to PD-1 blockade and protein-level implementation in FFPE HCC. (A, B) External anti–PD-1-treated HCC cohort: TLS RiskScore by response status (A) and response rates by TLS RiskScore group using the median cutoff (B) . In (B) , colors indicate the within-group proportions of responders and non-responders within each TLS RiskScore group. (C) Spatial transcriptomics mapping canonical TLS-associated chemokines (CXCL13, CCL19, CCL21) and signature signals for regulatory T cells (Treg) and conventional type 2 dendritic cells (cDC2) in representative HCC sections. (D, E) Representative TLS regions in FFPE HCC illustrating cDC2-predominant versus Treg-predominant cellular composition by H&E and multiplex immunofluorescence (mIF) staining (CD11c, CD1c, CD4, FOXP3, CD45, CD21). (F, G) Overall survival (OS) (F) and progression-free survival (PFS) (G) stratified by an mIF-based TLS RiskScore derived from TLS-region Treg (CD4 + FOXP3 + ) and cDC2 (CD11c + CD1c + ) measurements (median cutoff). (H) cDC2 fractions across TLS maturation stages. (I) Treg-to-cDC2 ratio across TLS maturation stages. **P < 0.01 and ****P < 0.0001.

    Journal: Frontiers in Immunology

    Article Title: Tumor immune microenvironment states inferred from TLS-associated immune-cell composition stratify prognosis in hepatocellular carcinoma

    doi: 10.3389/fimmu.2026.1818138

    Figure Lengend Snippet: TLS RiskScore association with response to PD-1 blockade and protein-level implementation in FFPE HCC. (A, B) External anti–PD-1-treated HCC cohort: TLS RiskScore by response status (A) and response rates by TLS RiskScore group using the median cutoff (B) . In (B) , colors indicate the within-group proportions of responders and non-responders within each TLS RiskScore group. (C) Spatial transcriptomics mapping canonical TLS-associated chemokines (CXCL13, CCL19, CCL21) and signature signals for regulatory T cells (Treg) and conventional type 2 dendritic cells (cDC2) in representative HCC sections. (D, E) Representative TLS regions in FFPE HCC illustrating cDC2-predominant versus Treg-predominant cellular composition by H&E and multiplex immunofluorescence (mIF) staining (CD11c, CD1c, CD4, FOXP3, CD45, CD21). (F, G) Overall survival (OS) (F) and progression-free survival (PFS) (G) stratified by an mIF-based TLS RiskScore derived from TLS-region Treg (CD4 + FOXP3 + ) and cDC2 (CD11c + CD1c + ) measurements (median cutoff). (H) cDC2 fractions across TLS maturation stages. (I) Treg-to-cDC2 ratio across TLS maturation stages. **P < 0.01 and ****P < 0.0001.

    Article Snippet: The antibody panel included CD45 (Aifang, AF20018), CD4 (Aifang, AF20210), FOXP3 (Maxim, MAB-1004), CD11c (Aifang, AF20381), CD21 (Aifang, AF20013), and CD1c (HUABIO, HA722562), each used at 1:200.

    Techniques: Spatial Transcriptomics, Multiplex Assay, Immunofluorescence, Staining, Derivative Assay